VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ESH CML 2022 | Management of pediatric CP-CML in the TKI era & additional considerations in this patient population

Nirmalya Roy Moulik, MD, PhD, MRCPCH, Tata Memorial Centre, Mumbai, India, comments on the treatment of children with chronic myeloid leukemia in the chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era, highlighting the long-term toxicities associated with TKI therapy in this patient population and the importance of monitoring these patients for adverse events to intervene where necessary. This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter